{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:28:41Z","timestamp":1779103721714,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006108","name":"NIH\/National Center for Advancing Translational Sciences","doi-asserted-by":"crossref","award":["UL1TR00457"],"award-info":[{"award-number":["UL1TR00457"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"NIH\/National Cancer Institute","doi-asserted-by":"crossref","award":["P30-CA08748-50"],"award-info":[{"award-number":["P30-CA08748-50"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"NIH\/National Cancer Institute","doi-asserted-by":"crossref","award":["P30 CA008748-50S6"],"award-info":[{"award-number":["P30 CA008748-50S6"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation of ASCO","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Comprehensive Cancer Center","award":["CA13873801"],"award-info":[{"award-number":["CA13873801"]}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Translational and Integrative Medicine Fund"},{"DOI":"10.13039\/100007052","name":"MSKCC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Annual Terry Fox Run for Cancer Research"},{"name":"Canada Club of New York"},{"name":"Carson Family Charitable Trust"},{"name":"Kate\u2019s Team"},{"name":"Commonwealth Cancer Foundation for Research"},{"name":"Experimental Therapeutics Center of MSKCC"},{"name":"Geoffrey Beene Cancer Foundation"},{"name":"Bocina Cancer Research Fund"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ymthe.2018.05.018","type":"journal-article","created":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T19:44:46Z","timestamp":1529091886000},"page":"1896-1905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy"],"prefix":"10.1016","volume":"26","author":[{"given":"Mark B.","family":"Geyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Rivi\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"S\u00e9n\u00e9chal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongzeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terence J.","family":"Purdon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meier","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean M.","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Halton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Lamanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurgen","family":"Rademaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Sadelain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renier J.","family":"Brentjens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2018.05.018_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J.\u00a0Clin."},{"key":"10.1016\/j.ymthe.2018.05.018_bib2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2018.05.018_bib3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2006-07-033274","article-title":"Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B\u00a0chronic lymphocytic leukemia","volume":"109","author":"Kay","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.05.018_bib4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.2008.16.4459","article-title":"Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses","volume":"27","author":"Lamanna","year":"2009","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2018.05.018_bib5","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.05.018_bib6","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2018.05.018_bib7","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T\u00a0cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.05.018_bib8","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T\u00a0cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.05.018_bib9","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T\u00a0cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2018.05.018_bib10","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T\u00a0cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2018.05.018_bib11","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.2016.34.15_suppl.3009","article-title":"Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T\u00a0cells directed against CD19 in patients (pts) with relapsed, refractory (R\/R) CLL","volume":"34","author":"Porter","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2018.05.018_bib12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood.V128.22.58.58","article-title":"Implications of Concurrent Ibrutinib Therapy on CAR T-Cell Manufacturing and Phenotype and on Clinical Outcomes Following CD19-Targeted CAR T-Cell Administration in Adults with Relapsed\/Refractory CLL","volume":"128","author":"Geyer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.05.018_bib13","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2018.05.018_bib14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/blood.V128.22.217.217","article-title":"Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"128","author":"Maude","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.05.018_bib15","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T\u00a0cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2018.05.018_bib16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2018.05.018_bib17","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T\u00a0cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2018.05.018_bib18","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T\u00a0cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2018.05.018_bib19","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2018.05.018_bib20","article-title":"Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine\/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation","volume":"128","author":"Lee","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.05.018_bib21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2018.05.018_bib22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2018.05.018_bib23","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ymthe.2018.05.018_bib24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.humpath.2016.04.019","article-title":"Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion","volume":"55","author":"Xiao","year":"2016","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ymthe.2018.05.018_bib25","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T\u00a0cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2018.05.018_bib26","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T\u00a0cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.05.018_bib27","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T\u00a0cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2018.05.018_bib28","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.2005.04.3836","article-title":"Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia","volume":"24","author":"Lamanna","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2018.05.018_bib29","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2018.05.018_bib30","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2018.05.018_bib31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.05.018_bib32","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.05.018_bib33","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.05.018_bib34","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1172\/JCI24176","article-title":"Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T\u00a0cells","volume":"115","author":"G\u00f6rg\u00fcn","year":"2005","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2018.05.018_bib35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood-2015-01-622936","article-title":"PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.05.018_bib36","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.05.018_bib37","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2013-01-476606","article-title":"Soluble ligands for NK\u00a0cell receptors promote evasion of chronic lymphocytic leukemia cells from NK\u00a0cell anti-tumor activity","volume":"121","author":"Reiners","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.05.018_bib38","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1182\/blood-2014-12-618025","article-title":"Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts","volume":"126","author":"Paggetti","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.05.018_bib39","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T\u00a0cells","volume":"19","author":"John","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2018.05.018_bib40","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1182\/blood.V128.22.816.816","article-title":"IL-18 Secreting CAR T Cells Enhance Cell Persistence, Induce Prolonged B Cell Aplasia and Eradicate CD19+ Tumor Cells without Need for Prior Conditioning","volume":"128","author":"Avanzi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.05.018_bib41","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T\u00a0cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.05.018_bib42","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/leu.2014.215","article-title":"IL-12-secreting CD19-targeted cord blood-derived T\u00a0cells for the immunotherapy of B-cell acute lymphoblastic leukemia","volume":"29","author":"Pegram","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2018.05.018_bib43","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2018.05.018_bib44","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/mt.2015.4","article-title":"Enhancing antitumor efficacy of chimeric antigen receptor T\u00a0cells through constitutive CD40L expression","volume":"23","author":"Curran","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.05.018_bib45","doi-asserted-by":"crossref","unstructured":"Park, J.H., Riviere, I., Wang, I., Senechal, B., Bernal, Y., Halton, E., Diamonte, C., Wang, Y., Brentjens, R.J., and Sadelain, M. (2017). A phase I trial of CD19-targeted EGFRt\/19\u201328z\/4-1BBL armored chimeric antigen receptor (CAR) modified T\u00a0cells in\u00a0patients with relapsed or refractory chronic lymphocytic leukemia. 10.1200\/JCO.2017.35.15_suppl.TPS7568.","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS7568"},{"key":"10.1016\/j.ymthe.2018.05.018_bib46","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2018.05.018_bib47","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0b013e318194a6e8","article-title":"Manufacturing validation of biologically functional T\u00a0cells targeted to CD19 antigen for autologous adoptive cell therapy","volume":"32","author":"Hollyman","year":"2009","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.ymthe.2018.05.018_bib48","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001618302211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001618302211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T10:32:10Z","timestamp":1571481130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001618302211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1525001618302211"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.05.018","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018","name":"copyright","label":"Copyright"}]}}